PharmAust Ltd (ASX: PAA) Share Price and News

Dr Aston served as Chief Executive Officer of Mayne Pharma Group until 15 February 2012. During his career, he has been involved in start-up companies and major pharmaceutical companies. Aspects of his experience include FDA and EU product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston is both a scientist and seasoned biotechnology entrepreneur, with a record in both fields.

Mr Bassett has spent more than 35 years working in accounting, finance and stockbroking. During that time, he has had involvement in Australian financial markets including public Company listings and capital raisings, as well as mergers and acquisitions. In 1991, he became a Director/Councillor of the Royal Flying Doctor Service (RFDS) in WA and he was Chairman of RFDS Western Operations for eight years until his retirement in 2017. He also served six years as Western Operations representative on the Board of the Australian Council of the Royal Flying Doctor Service of Australia.

Mr Wright has twenty years of experience in the administration of ASX listed companies, corporate governance and corporate finance. He also fills the role of Director and Company Secretary with several unlisted companies. Mr Wright is the Managing Director of Perth-based corporate advisory firm Straight Lines Consultancy, specialising in the provision of corporate services to public companies. Mr Wright has experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, and shareholder relations with both retail and institutional investors.

Mr Bishop has 35 years of experience in corporate finance and equity capital markets. Having worked in London and Sydney, first as a lawyer at Linklaters & Paines and Allen, Allen & Hemsley; and then as a stockbroker and investment banker at Ord Minnett, Robert Fleming and, since 1998, at his Sydney based corporate finance business, First Capital Markets. He has experience in the areas of stock market flotation's, licensing and compliance work.

Dr Duthy has over 19 years of direct financial market and executive level/Board experience with ASX-listed companies. He is a Director and Founder of Nemean Group. This has included an IR/Corporate Development consultancy role with Nova Eye Medical (ASX:EYE). In addition, Dr Duthy was IR lead for Limeade Inc. (ASX:LME) which was acquired by WebMD Health Services (NASDAQ: WBMD) in August 2023. Prior to this Dr Duthy was the former Head of Corporate Development and IR at Sirtex Medical (ASX:SRX). Dr Duthy is currently Non-Executive Chairman of Arovella Therapeutics (ASX:ALA), and an Executive Director of Neurotech International Ltd (ASX:NTI) and Invex Therapeutics (ASX:IXC).

-